Bronchial thermoplasty is a bronchoscopic procedure to reduce the mass of airway smooth muscle and attenuate bronchoconstriction. We examined the effect of bronchial thermoplasty on the control of moderate or severe persistent asthma.
Among people with asthma, lower socioeconomic status, education level, and ethnic minority status clearly have undesirable effects on their care and outcomes. Patients with severe disease who attend county (public) hospitals in the United States tend to have less access to resources, which, in addition to environmental and compliance issues, may contribute to poorer disease control.
University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, and Jeffrey A. Rivest, MS, President and Chief Executive Officer of University of Maryland Medical Center (UMMC), today announced the official launch of a new "Program in Lung Healing," that will further the School's position as a national leader in research, education and clinical innovation for acute ailments of the lung and respiratory system.
Internationally, severe asthma is defined as anybody who is on maximum therapy, which has no measurable side effects, but still have symptoms of persistent asthma. In the UK, that effectively means people who require oral steroids for their asthma two or more times a year.
Like millions of people, Jeannine Childs suffers from asthma. But unlike most, her asthma was debilitating. For years she struggled with wheezing, shortness of breath and fits of coughing so severe that they often landed her in the hospital. Nothing was really working – not lifestyle changes, not medications.
The beneficial effects of bronchial thermoplasty, a non-pharmacologic treatment for asthma, last at least five years, according to researchers at National Jewish Health and other institutions.
Researchers have shown that the asthma-control benefits of bronchial thermoplasty remain for as long as 5 years following treatment.
Overlake Medical Center in Bellevue is now the only hospital in King County offering bronchial thermoplasty to patients suffering from severe asthma, giving them a non-medicated, proven way to control their asthma symptoms and resulting in 32 percent fewer severe asthma attacks.
Five-year data from the Asthma Intervention Research 2 clinical trial presented today demonstrated that the Boston Scientific Corporation Alair Bronchial Thermoplasty System continues to show therapy benefits in adult patients with severe uncontrolled asthma.
There is still no cure for asthma, so for 22 million people in the U.S., this chronic disease continues to be a daily burden no matter where they live. But it's not just air pollution they should be worried about. Factors such as pollen, secondhand smoke – even high rates of poverty, a large uninsured population or a high number of ER visits – can be critical signs that certain cities and states are worse for families with asthma. It is especially true for people with severe asthma.
Nearly 24 million people in this country suffer from asthma. For most of them, avoiding allergens and taking medications help keep their asthma under control. But for a small group with severe persistent asthma, frequent hospital visits tend to be the norm and taking medications and lifestyle changes don't do the trick. Northwestern Memorial Hospital is now using a new procedure called bronchial thermoplasty (BT), the first non-drug therapy approved by the Federal Drug Administration, for patients with severe asthma.
The U.S. Food and Drug Administration has granted Boston Scientific Corporation regulatory approval for its S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).
For two decades, Patricia DiGiusto struggled with severe asthma. Powerful medications and frequent use of her inhaler could not prevent repeated trips to the emergency room. ... Two years ago, Ms. DiGiusto's doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.
Doctors at Orlando Regional Medical Center (ORMC) are delivering heat directly to the source to treat patients with severe asthma - a respiratory disease that causes the airways in the lungs to narrow, making it difficult to breathe.
Hannah Andrews, 23, who has suffered from severe asthma since she was a child, is breathing easier now thanks to a new procedure offered at Vanderbilt known as bronchial thermoplasty.
Boston Scientific Corporation welcomes a milestone in private insurance reimbursement coverage for bronchial thermoplasty (BT) performed using the Alair Bronchial Thermoplasty System. Minnesota-based HealthPartners and Michigan-based Priority Health recently issued the first public postings of positive insurance coverage policies providing their respective memberships with reimbursement for this novel procedure to treat severe asthma.
Boston Scientific Corporation announced that the Centers for Medicare and Medicaid Services (CMS), the agency that administers the Medicare program, has acknowledged the substantial clinical improvement associated with the use of the Alair Bronchial Thermoplasty System to perform bronchial thermoplasty for the management of severe asthma.
Boston Scientific Corporation today announced long-term safety data from the Research in Severe Asthma (RISA) Trial, which demonstrated the maintenance of stable lung function and the absence of clinical complications over a five-year period in patients with severe refractory asthma treated with its Alair Bronchial Thermoplasty System.
Today on World Asthma Day 2011, despite decades of progress on the management and control of asthma – more research, better understanding and powerful treatments – millions of people with severe asthma are still living with serious, frequent, life-threatening symptoms.
If you have severe persistent asthma, bronchial thermoplasty (BT) may help you stop taking long-acting beta2-agonists (LABAs) according to a new study presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix, Nov. 11-16. This novel procedure delivers thermal energy to the airway wall to reduce airway constriction.
Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced that it has received an award from the Departments of the Treasury and Health and Human Services for the Qualifying Therapeutic Discovery Project (QTDP.)